Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy

Cheng,Wei; Ainiwaer,Aimudula; Xiao,Lei; Cao,Qian; Wu,Ge; Yang,Ying; Mao,Rui; Bao,Yongxing

doi:10.3892/mmr.2015.3725

Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy

Authors:
- Wei Cheng
- Aimudula Ainiwaer
- Lei Xiao
- Qian Cao
- Ge Wu
- Ying Yang
- Rui Mao
- Yongxing Bao
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, P.R. China
Published online on: May 4, 2015 https://doi.org/10.3892/mmr.2015.3725
Pages: 2451-2456
Copyright: © Cheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to determine the correlation between hepatocellular carcinoma (HCC) and heat shock protein 90 (HSP90), involved in tumor angiogenesis, and to evaluate the effect of AUY922, a HSP90 inhibitor, in HCC. The expression of HSP90 and microvessel density (MVD) were measured in tissue samples from 76 patients with HCC by immunohistochemistry. Western blot analysis was performed to detect the expression of HSP90 in the HCC tissues and different HCC cell lines. The effects of time and concentration treatment with the AUY922 HSP90 inhibitor were investigated in HepG2 cells. Cell proliferation was measured using an MTT assay and a Transwell assay was performed to evaluate the migration of the HepG2 cells following treatment with different concentrations of AUY922. Positive staining of HSP90 was observed in 88.16% (67/76) of the HCC tissues, compared with 16.67% (4/24) of the normal tissues. The difference in the expression of HSP90 between the HCC and normal tissues was statistically significant (P<0.001). Tumors exhibiting positive expression of HSP90 had significantly higher MVD compared with the HSP90‑negative counterparts (82.8±12.44 vs. 23.8±8.07, respectively; P<0.001). The expression levels of HSP90 were positively correlated with MVD in all the tissue samples (r_s=0.724; P<0.001). AUY922 inhibited the proliferation of the HepG2 cells in a time‑ and concentration‑dependent manner, and the migration of HepG2 cells was distinctly suppressed following treatment with AUY922. These data suggested that the angiogenesis of human HCC may be mediated by HSP90, and that the specific HSP90 inhibitor, AUY922, has a therapeutic role in the treatment of HCC. Therefore, HSP90 may represent a selective target in molecularly targeted treatment of HCC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Ades S: Adjuvant chemotherapy for colon cancer in the elderly: moving from evidence to practice. Oncology (Williston Park). 23:162–167. 2009.
3	Frangov T, Gaĭdarski R, Dimitrova V, Popov V, Grozeva K and Rusenov D: Prognostic factors for survival in primary liver cancer. Khirurgiia (Sofiia). 6:36–39. 2007.In Bulgarian.
4	Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
5	Fidler IJ and Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 79:185–188. 1994. View Article : Google Scholar : PubMed/NCBI
6	Ferrara N: Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol. 280:C1358–C1366. 2001.PubMed/NCBI
7	Weidner N: Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol. 147:9–19. 1995.PubMed/NCBI
8	Xu YZ, Zhu Y, Shen ZJ, Sheng JY, He HC, Ma G, et al: Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiongenesis: Potential for therapy. Endocrine. 40:445–451. 2011. View Article : Google Scholar : PubMed/NCBI
9	Trepel J, Mollapour M, Giaccone G and Neckers L: Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 10:537–549. 2010. View Article : Google Scholar : PubMed/NCBI
10	Lee KH, Lee JH, Han SW, Im SA, Kim TY, Oh DY and Bang YJ: Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins. Cancer Sci. 102:1388–1395. 2011. View Article : Google Scholar : PubMed/NCBI
11	Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, Patterson L, de Haven Brandon A, Gowan S, Boxall F, Aherne W, et al: NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis and metastasis. Cancer Res. 68:2850–2860. 2008. View Article : Google Scholar : PubMed/NCBI
12	Xu Y, Zhang C, Chen D, Zhao J, Shen Z, Wu Y and Zhu Y: Effect of HSP90 inhibitor in pheochromocytoma PC12 cells: an experimental investigation. Tumour Biol. 34:4065–4071. 2013. View Article : Google Scholar : PubMed/NCBI
13	Laforga JB and Aranda FI: Angiogenic Index: A new method for assessing microvascularity in breast carcinoma with possible prognostic implications. Breast J. 6:103–107. 2000. View Article : Google Scholar
14	Geng J, Li X, Zhou Z, Wu CL, Dai M and Bai X: EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer. Cancer Lett. 359:275–287. 2015. View Article : Google Scholar : PubMed/NCBI
15	Pearl LH, Prodromou C and Workman P: The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J. 410:439–453. 2008. View Article : Google Scholar : PubMed/NCBI
16	Pratt WB and Toft DO: Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood). 228:111–133. 2003.
17	Powers MV and Workman P: Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer. 13(Suppl 1): 125–135. 2006. View Article : Google Scholar
18	Gartner EM, Silverman P, Simon M, Flaherty L, Abrams J, Ivy P and Lorusso PM: A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer. Breast Cancer Res Treat. 131:933–937. 2012. View Article : Google Scholar
19	Eiseman JL, Lan J, Lagattuta TF, et al: Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino) ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol. 55:21–32. 2005. View Article : Google Scholar
20	Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes DaGama EM, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu LP, et al: Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol. 7:818–826. 2011. View Article : Google Scholar : PubMed/NCBI
21	Nguyen DM, Lorang D, Chen GA, Stewart JH IV, Tabibi E and Schrump DS: Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. Ann Thorac Surg. 72:371–378; discussion 378–379. 2001. View Article : Google Scholar : PubMed/NCBI
22	Hur E, Kim HH, Choi SM, et al: Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol. Mol Pharmacol. 62:975–982. 2002. View Article : Google Scholar : PubMed/NCBI
23	Pacey S, Gore M, Chao D, Banerji U, Larkin J, Sarker S, et al: A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest New Drugs. 30:341–349. 2012. View Article : Google Scholar
24	Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, et al: NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis and metastasis. Cancer Res. 68:2850–2860. 2008. View Article : Google Scholar : PubMed/NCBI
25	Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, et al: NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res. 10:R332008. View Article : Google Scholar : PubMed/NCBI
26	Moser C, Lang SA, Hackl C, Wagner C, Scheiffert E, Schlitt HJ, et al: Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer. Anticancer Res. 32:2551–2561. 2012.PubMed/NCBI
27	Chatterjee M, Andrulis M, Stuhmer T, Müller E, Hofmann C, Steinbrunn T, et al: The PI3K/Akt signalling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. Haematologica. 98:1132–1141. 2013. View Article : Google Scholar :
28	Ueno T, Tsukuda K, Toyooka S, Ando M, Takaoka M, Soh J, et al: Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer. Lung Cancer. 76:26–31. 2012. View Article : Google Scholar